Psychedelics
Receipt of acute care for hallucinogen use predicts greater mortality risk within 5 years
Individuals in Canada who received hospital care for hallucinogen use had greater 5-year mortality risk, especially from suicide, compared with the general population, according to a study published in Canadian Medical Association Journal.
Survey: No clear consensus on psychological support strategies in psychedelic treatment
Opinions varied among practitioners regarding psychological support when treating with psychedelics, although an emotive approach was slightly preferred, according to results of a survey published in Journal of Clinical Psychiatry.
High-dose psilocybin may help treat depressive symptoms, with small effect size
High-dose psilocybin showed the potential to treat depressive symptoms, although the effect size appeared small and comparable to that of escitalopram, according to results of a network meta-analysis published in The BMJ.
FDA’s MDMA ruling raises the bar for psychedelic research
There are two FDA-approved medications for PTSD, both selective serotonin reuptake inhibitors. The FDA has not approved a new medication for PTSD since 2001.
Healio wins APEX award for Psychedelics & Alternative Therapies collection
The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.
FDA rejects MDMA-assisted PTSD therapy, requests additional data
The FDA on Aug. 9 issued a complete response letter to Lycos Therapeutics for its new drug application regarding midomafetamine capsules for the treatment of PTSD, citing insufficient data to approve and requesting an additional phase 3 trial.
VIDEO: ‘New hope on the horizon’ in psychedelic medicine
NEW YORK — In this Healio Video Perspective, Reid Robison, MD, MBA, senior principal investigator at Numinus, a company that conducts clinical trials in psychedelics, discusses promising new treatment options for psychiatric conditions.
Illegal hallucinogens found in mushroom gummies sold at gas stations, smoke shops
Mushroom-containing nootropic gummies sold at gas stations and smoke shops in Virginia contained unlabeled psilocybin and psilocin, according to results of an investigation published in Morbidity and Mortality Weekly Report.
Clearmind Medicine obtains rights to psychedelic compounds to treat PTSD, mental health
Clearmind Medicine, a clinical-stage biotech company, has attained exclusive global rights to develop, produce and commercialize compounds designed to treat PTSD and other mental health conditions, according to a press release.
'It just needs to be better studied': FDA advisory committee rejects MDMA for PTSD
An FDA advisory committee voted against recommending a psychedelic treatment for PTSD, citing insufficient data for what many described as a still-promising path forward.